On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for Trodelvy (sacituzumab govitecan-hziy; SG) for adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. Also Read: Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles. The decision was made in consultation with the FDA and does not affect the other approved Trodelvy indi…
